anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Propofol
Trial phase: Phase 3
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 83
Group description: Propofol for induction of general anesthesia.

Propofol: Propofol for induction of general anesthesia.
Eligibility criteria:
Inclusion Criteria:

Subjects undergoing elective surgery (nonemergency, noncardiothoracic, and nonintracranial surgery anticipated to last at least 1 hour ).
Males or females, aged ≥18 years old, with American Society of Anesthesiologists Physical Status (ASA PS) I to IV.
Body mass index (BMI) ≥18 kg/m2.
For all females of childbearing potential, negative pregnancy test at screening and baseline. Additionally, females of childbearing potential must agree to use birth control (such as condom, intrauterine device [IUD], abstinence) from the time of consent until 30 days post study drug administration.
Capable of understanding the procedures and methods of this study, willing to sign an Informed Consent Form, and to complete this study in strict compliance with the study protocol.

Exclusion Criteria:

Contraindications to deep sedation/general anesthesia or a history of adverse reaction to sedation/general anesthesia.
Known to be allergic to eggs, soy products, opioids and their antidotes, or propofol; subject having contraindications to propofol, opioids, and their antidotes.
Medical condition or evidence of increased sedation/general anesthesia risk.
Management risks of respiratory tract and judged by the investigator to be unsuitable for inclusion in the study.
Any medication that has the potential to interact synergistically with propofol or HSK3486, including but not limited to all sedatives and hypnotics.
Laboratory parameters significantly out of range at screening.
Female subjects with a positive pregnancy test (serum or urine) at screening or baseline; lactating subjects; any subject planning to get pregnant within 1 month after the study (including the male subject's partner).
Judged by the investigator to have any other factors that make the subject unsuitable for participation in the study.
Intervention: Hesperidin
Trial phase: Phase 2
SMILES: COc1ccc([C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 107
Group description: Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Eligibility criteria:
Inclusion Criteria:

Covid-19 positive by polymerase chain reaction (PCR) testing;
Participant must be able to evaluate their symptoms and report them in the symptoms diary;
Patients must be able to take their oral temperature daily with an electronic thermometer provided to them with study materials;
Males and females, at least 18 years of age, capable and willing to provide informed consent;
Female patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile, or is of childbearing potential and practicing at least one method of contraception and preferably two complementary forms of contraception including a barrier method (e.g. male or female condoms, spermicides, sponges, foams, jellies, diaphragm, intrauterine device (IUD)) throughout the study;
Patient must have received a diagnosis of COVID-19 infection within the last 48 hours and have one or more symptoms;
Outpatient setting (not currently hospitalized or under immediate consideration for hospitalization);
Patient must be able and willing to comply with the requirements of this study protocol.

Exclusion Criteria:

Patient currently hospitalized or under immediate consideration for hospitalization;
Patient currently in shock or with hemodynamic instability;
Patient undergoing chemotherapy for cancer;
Patient is unable to take oral temperature using an electronic thermometer;
Patient who received at least one dose of the COVID-19 vaccine;
Female patient who is pregnant or breast-feeding or is considering becoming pregnant during the study;
People taking anticoagulant/antiplatelet medications, those with bleeding disorders, and people two weeks before or after surgery;
Patient is considered by the investigator, for any reason, to be an unsuitable candidate for the study;
Regular consumption of natural products containing more than 150 mg of hesperidin or regular consumption of more than 1 glass of orange juice per day;
Known allergy to any of the medicinal and non-medicinal ingredient: hesperidin, microcrystalline cellulose, magnesium stearate.
Intervention: Sufentanil
Trial phase: Phase 4
ATC code: N01AH03
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCc2cccs2)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Subjects will receive dose of Dsuvia 30mcg SL (1st dose) after induction but before first incision. Post-operatively, if subject rates pain higher than 4 out of 10, subject will receive a second dose of Dsuvia 30mcg SL (sublingual). If 30 minutes after second dose, subject rates pain higher than 4 out of 10, subject will receive ibuprofen 800mg IV. If 60 minutes after second dose, subject rates pain higher than 7 out of 10, subject will receive hydromorphone 0.4 mg IV.

Dsuvia: Subject will receive up to 2 doses of Dsuvia. The first dose will be intra-op and the second dose will be post-op (if needed)
Eligibility criteria:
Inclusion Criteria:

Age range 18-100 years
Currently taking Suboxone
ASA (American Society of Anesthesiology) physical score 1-3
Able to provide a signed informed consent
General anesthesia (either endotracheal intubation or laryngeal mask airway) or MAC (monitored anesthesia care) without the use of regional anesthesia

Exclusion Criteria:

Known allergic reactions to Dsuvia and its excipients
Severe respiratory illness including exacerbation of asthma attack
Significant intraoperative hemodynamic instability
Use of Regional anesthesia techniques
Intervention: Tetracycline hydrochloride
Trial phase: Not Applicable
SMILES: CN(C)C1C(=O)C(C(N)=O)=C(O)C2(O)C(=O)C3=C(O)c4c(O)cccc4C(C)(O)C3CC12.Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 50
Group description: 4 drops of tetracycline hydrochloride 3% (APT™ T3X) applied inside of the nasal channels and inside of nostrils, once a day, every day for 21 days (except health professionals that will be instructed to use 4 drops of APT™ T3X twice a day, every day for 21 days.

Tetracycline hydrochloride 3%: Proprietary formulation composed of FDA approved inactive ingredients and the active pharmaceutical ingredient tetracycline hydrochloride.
Eligibility criteria:
Inclusion Criteria:

good general health (without serious health problems);
tested negative, by means of immunoglobulin (Ig) G and IgM serology tests and chain real-time polymerase chain reaction (RT-PCR), for COVID-19.

Exclusion Criteria:

previous immunization against COVID-19;
allergy to tetracycline hydrochloride;
diagnosis of Lyme disease;
immunocompromised;
share housing with someone diagnosed with COVID-19 at the time of the baseline evaluation;
serious illnesses, such as cancer, kidney failure, decompensated cardiorespiratory and metabolic diseases, etc.
Intervention: Tazarotene
Trial phase: Phase 4
ATC code: D05AX05 | D05AX55
SMILES: CCOC(=O)c1ccc(C#Cc2ccc3c(c2)C(C)(C)CCS3)nc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Participants with plaque type psoriasis to be treated with Duobrii® (halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ) to be applied thinly once a day on the affected areas of hands and/or feet at weeks 0,2,8,16 for a total of 24 weeks.
Eligibility criteria:
Inclusion Criteria

Subject is able to provide written, informed consent and comply with the study protocol.
Subject is at least 18 years of age.
Subject has a diagnosis of plaque-type palmar and/or plantar psoriasis.
Patient has at least one psoriatic plaque outside of the palms and soles or psoriatic nail findings.
Subject has a ppPGA ≥ 3 at screening/baseline visit.

Subject is using adequate birth control during the study period as defined as follows:

Option 1: Any one of the following highly effective methods: hormonal contraception (oral, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation; or partner's vasectomy; OR

Option 2: Male or female condom (latex condom or nonlatex condom NOT made out of natural [animal] membrane [for example, polyurethane]; PLUS one additional barrier method: (a) diaphragm with spermicide; (b) cervical cap with spermicide; or (c) contraceptive sponge with spermicide.

OR

Option 3: Abstinence from sex when it is a lifestyle choice, and not just a social circumstance.

Exclusion Criteria

Subject is not able to provide written, informed consent and comply with the study protocol.
Subject is less than 18 years of age.
Subject has non-plaque type psoriasis on the hands and/or feet.
Patient does not have any evidence of psoriasis elsewhere.
Subject has concurrent cutaneous disease affecting the hands and/or feet that would interfere with assessments.
Subject has a ppPGA < 3 at screening/baseline visit.
Subject refuses to discontinue concomitant prescription medications on hands and/or feet.
Subject has used topical prescription treatments or received phototherapy treatment for psoriasis within 2 weeks of screening/baseline visit.
Subject has used intralesional kenalog within 4 weeks of screening/baseline visit.
Subject has taken oral treatments for psoriasis within 4 weeks of screening/baseline visit.
Subject has received any treatment with biologic medications within 5 half-lives (if known) or 16 weeks prior to screening/baseline, whichever is longer.
Subject refuses to use adequate birth control during the duration of the study period.
Subject is currently pregnant or breastfeeding.
Intervention: Albendazole
Trial phase: Phase 3
ATC code: P02CA03
SMILES: CCCSc1ccc2nc(NC(=O)OC)[nH]c2c1
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 84
Group description: Placebo (for moxidectin, 4 tablets) and albendazole (Zentel®, 1 tablet of 400 mg) administered orally at day 0

Albendazole 400 mg Oral Tablet: Tablets of 400 mg albendazole
Eligibility criteria:
Inclusion Criteria:

Aged between 12 and 60 years
Written informed consent signed by either parents/caregivers for underage adolescents (aged 12-17 years) or by the participant him/herself (18-60 years of age); and written assent by underage participant
Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and at follow-up assessment 14-21 days after treatment
Willing to be examined by a study physician prior to treatment
At least two slides of the quadruple Kato-Katz thick smears positive for T. trichiura and infection intensities of at least 48 EPG

Exclusion Criteria:

Presence or signs of major systemic illnesses, e.g. body temperature ≥ 38°C, severe anemia (below 80g/l Hb according to WHO) upon initial clinical assessment
Known or suspected infection with Loa loa
History of acute or severe chronic disease
Abnormal liver function assessed by multiple biochemical blood-based analyses
Recent use of anthelmintic drug (within past 4 weeks)
Attending other clinical trials during the study
Pregnancy, lactating, and/or planning to become pregnant within the next 3 months
Known allergy to study medications (i.e. albendazole, ivermectin or moxidectin)
Taking medication with known contraindication to or interaction with study drugs
Intervention: Betamethasone
Trial phase: Phase 4
ATC code: A01AC02 | A07EA04 | C05AA05 | C05AA09 | D07AB19 | D07AC01 | D07BC01 | D07CB04 | D07CC01 | D07XB05 | D07XC01 | D10AA03 | H02AB01 | H02AB02 | R01AD03 | R01AD06 | R01AD53 | R03BA04 | S01BA01 | S01BA06 | S01BB04 | S01CA01 | S01CA05 | S01CB01 | S01CB04 | S02BA06 | S02BA07 | S02CA06 | S03BA01 | S03BA03 | S03CA01 | S03CA06
SMILES: CC1CC2C3CCC4=CC(=O)C=CC4(C)C3(F)C(O)CC2(C)C1(O)C(=O)CO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone. Following surgery, the participant will be provided with a 1) six-day oral methylprednisolone taper course.

Glucocorticoids: Patients will receive a single intraoperative dose of 10mg of intravenous dexamethasone intraoperatively. Following surgery, the participant will be provided with a six-day oral methylprednisolone taper course.
Eligibility criteria:
Inclusion Criteria

• All adults ≥18 years old with an isolated, intra-articular traumatic elbow fracture to be treated at Vanderbilt University Medical Center with operative intervention and a standardized post-operative rehab protocol.

Intra-articular elbow fracture defined as:

Distal humerus
Proximal ulna
Radial head fracture
Combination fracture of two or more of the above
Radiographs present confirming intra-articular injury

Exclusion Criteria

Patients with bilateral elbow fractures
Patients with an altered mental status
Pregnant
Allergy or contra-indication to glucocorticoid administration
Type 1 or Type 2 diabetes
Pre-injury limitation in elbow range or motion (patient reported)
Unable to provide consent for themselves
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.

Saline: Patients will receive a single intraoperative dose of 10 mg of saline. Following surgery, the participant will be provided with a six-day placebo course.
Eligibility criteria:
Inclusion Criteria

• All adults ≥18 years old with an isolated, intra-articular traumatic elbow fracture to be treated at Vanderbilt University Medical Center with operative intervention and a standardized post-operative rehab protocol.

Intra-articular elbow fracture defined as:

Distal humerus
Proximal ulna
Radial head fracture
Combination fracture of two or more of the above
Radiographs present confirming intra-articular injury

Exclusion Criteria

Patients with bilateral elbow fractures
Patients with an altered mental status
Pregnant
Allergy or contra-indication to glucocorticoid administration
Type 1 or Type 2 diabetes
Pre-injury limitation in elbow range or motion (patient reported)
Unable to provide consent for themselves
Intervention: Psilocybin
Trial phase: Phase 2
SMILES: CN(C)CCc1c[nH]c2cccc(OP(=O)(O)O)c12
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: 25 mg COMP360 Psilocybin

Psilocybin: Open label
Eligibility criteria:
Inclusion Criteria:

Signed ICF.
18 years of age or older
At least moderate MDD
Hamilton Depression Rating Scale (17 item) score ≥18
Currently receiving treatment with a selective serotonin reuptake inhibitor
Failure to respond to an adequate dose and duration of 2, 3, or 4 pharmacological treatments
McLean Screening Instrument for Borderline Personality Disorder <7 at Screening (V1).
Ability to complete all protocol required assessment tools without any assistance or alteration to the copyrighted assessments, and to comply with all study visits.

Exclusion Criteria:

Psychiatric Exclusion Criteria:

Current or past history of schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), bipolar disorder, delusional disorder, paranoid personality disorder, schizoaffective disorder, or borderline personality disorder, as assessed by medical history, McLean Screening Instrument for Borderline Personality Disorder and a structured clinical interview (version 7.0.2 MINI).
Prior electroconvulsive therapy and/or ketamine for current episode.
Ongoing use of an antidepressant medication, including augmentation or combination therapies, other than a single SSRI
Current psychological therapies that will not remain stable within 21 days of the psilocybin session. Psychological therapies cannot be initiated within 21 days of baseline.
Current (within the last year) alcohol or substance use disorder as informed by DSM 5 (diagnosed by MINI 7.0.2) at Screening (V1).
Significant suicide risk as defined C-SSRS within the past year
Depression secondary to other severe medical conditions according to clinicians' judgement.

Other personal circumstances and behaviour judged to be incompatible with establishment of rapport or safe exposure to psilocybin, including exposure to psilocybin within the past year and use of psychedelics, such as ayahuasca, during the current depressive episode.

General Medical Exclusion Criteria:

Women who are pregnant, nursing or planning a pregnancy.
Cardiovascular conditions
Uncontrolled or insulin dependent diabetes.
Seizure disorder.
Positive urine drug screen for illicit drugs or drugs of abuse
Current enrolment in any investigational drug or device study or participation in such within 30 days prior to Screening (V1).
Current enrolment in another clinical study of an investigational medical or participation in such within 30 days of Screening (V1).
Abnormal and clinically significant results on the physical examination, vital signs, ECG or laboratory tests at Screening (V1).
Any other clinically significant cardiovascular, pulmonary, gastrointestinal, hepatic, renal or any other major concurrent illness that, in the opinion of the investigator, may interfere with the interpretation of the study results or constitute a health risk for the participant if he/she takes part in the study.
Intervention: Atogepant
Trial phase: Phase 3
ATC code: N02CD07
SMILES: C[C@@H]1[C@H](c2c(F)ccc(F)c2F)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 156
Group description: Participants received atogepant 60 mg, orally, QD for up to 12 weeks in a DB treatment period.
Eligibility criteria:
Inclusion Criteria:

At least a 1-year history of migraine with or without aura consistent with a diagnosis according to the ICHD-3, 2018.
Age of the participant at the time of migraine onset < 50 years -History of 4 to 14 migraine days per month on average in the 3 months prior to Visit 1 in the investigator's judgment
Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period.
4 to 14 migraine days in the 28-day baseline period per eDiary
Failed oral migraine prophylaxis medications from 2 to 4 medication classes

Exclusion Criteria:

Any clinically significant hematologic, endocrine, pulmonary, hepatic, gastrointestinal, or neurologic disease
Participant has any other concurrent pain condition that, in the opinion of the investigator, may significantly impact the current headache disorder
In the opinion of the investigator, confounding psychiatric conditions, dementia, epilepsy, or significant neurological disorders other than migraine
Has ≥ 15 headache days per month on average across the 3 months prior to Visit 1 in the investigator's judgment
Has ≥ 15 headache days in the 28-day baseline period per eDiary
Clinically significant cardiovascular or cerebrovascular disease
Has a history of migraine accompanied by diplopia or decreased level of consciousness or retinal migraine as defined by ICHD-3, 2018
Has a current diagnosis of chronic migraine, new persistent daily headache, medication overuse headache, trigeminal autonomic cephalgia (eg, cluster headache), or painful cranial neuropathy as defined by ICHD-3, 2018
Intervention: Gersizangitide
Trial phase: Phase 1 | Phase 2
SMILES: CCC(C)C(NC(=O)C(CC(=O)O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(Cc1ccccc1)NC(=O)C1CCCN1C(=O)C(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccccc1)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(N)CC(C)C)C(C)O)C(C)CC)C(=O)NC(CC(N)=O)C(=O)NC(CC(=O)O)C(=O)NC(C(=O)NC(C(=O)NC(CC(N)=O)C(=O)NC(Cc1ccccc1)C(N)=O)C(C)CC)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: AXT107 0.1 mg/eye

AXT107 0.1 mg: Single intravitreal injection of AXT107 0.1 mg/eye (low dose)
Eligibility criteria:
Inclusion Criteria:

Patients 50 years of age or older diagnosed in the study eye with subfoveal choroidal neovascularization (CNV) or juxtafoveal CNV secondary to AMD
Best corrected visual acuity (BCVA) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 65 to 10 in the study eye
Willing and able to comply with clinic visits and study-related procedures
Provide signed inform consent

Exclusion Criteria:

Macular edema or CMV secondary to any causes other than AMD in the study eye
Previously-treated patients who are not responders to anti-VEGF
Any condition that may preclude improvement in visual acuity in the study eye
Previous vitreoretinal surgery, filtration surgery, and cataract surgery within 3 months in the study eye

Note: Other inclusion/exclusion criteria apply
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: The surgeon will administer injectable saline as a cranial block according to a technique previously described by Pinosky et al (Pinosky et al., 1996). The supraorbital, supratrochlear, zygomaticotemporal, auriculotemporal, postauricular lesser and greater occipital nerve branches on the ipsilateral side of the operation will be blocked with 5-10 cc of solution (with a maximum of 60 cc at all sites) by needle infiltration. This process generally takes 1-2 minutes. Following this, the general anesthesia is lightened and the patient is extubated in usual fashion.

Saline: Used as cranial block for craniotomy surgery
Eligibility criteria:
Inclusion Criteria:

≥18 years of age
Need for elective supratentorial craniotomy
Preoperative GCS > 13

Exclusion Criteria:

Preoperative GCS ≤ 13
Child (<18 years of age)
Inability to understand or use the visual analog scale (VAS)
Proven or suspected allergy to local anesthetics
Craniotomy incision extending beyond the field of the block
Patients chronically (more than 2 wk) treated with narcotic medications
Previous scalp incision
Bilateral craniotomies
Allergies to local anesthetics
GCS verbal score < 4 after extubation
Patients whose surgeries extend past 6 hours (will be placed on standard of care and removed from study)
Patients currently on ergot-type oxytoxic drugs, MAOIs, or certain antidepressants
Lactating Mothers